PA
TERN

Profund Advisors’s Terns Pharmaceuticals TERN Stock Holding History

Profund Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$351K Sell
6,666
-595
-8% -$24.4K 0.01% 669
2025
Q4 		$293K Sell
7,261
-5,498
-43% -$127K 0.01% 891
2025
Q3 		$95.8K Buy
+12,759
New +$81.5K ﹤0.01% 1035

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Profund Advisors's TERN Position: Q1 2026 in Review

Profund Advisors reduced its Terns Pharmaceuticals (TERN) stake by 8.2% in Q1 2026, selling an estimated $24.4K and leaving 6,666 shares worth $351K. The position accounts for 0.01% of the portfolio, ranked #669.

Profund Advisors first reported a position in TERN in Q3 2025 and has held it in 3 quarters since. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • Profund Advisors held 6,666 shares of Terns Pharmaceuticals worth $351K as of Q1 2026.
  • Profund Advisors sold 595 Terns Pharmaceuticals shares in Q1 2026, an estimated $24.4K.
  • Terns Pharmaceuticals made up 0.01% of Profund Advisors's portfolio in Q1 2026, its #669 holding.
  • Profund Advisors first reported a position in Terns Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.